Polymyalgia Rheumatica Market Anticipated To Witness Robust Growth, Surpassing $1.73 Billion By 2029

The Polymyalgia Rheumatica Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Polymyalgia Rheumatica Market Size and Its Estimated Growth Rate?
In the past few years, the polymyalgia rheumatica market has seen robust growth. Projections indicate that an increase from $1.28 billion in 2024 to $1.36 billion in 2025, at a 6.6% compound annual growth rate (CAGR). This historical growth can be credited to greater knowledge in the health services sector, an increase in the utilization of corticosteroids, the expansion of specialty clinics, the advent of biologic therapies, and growing healthcare budgets.

Significant enhancements are predicted for the polymyalgia rheumatica market in the coming years. The market is estimated to reach $1.73 billion by 2029, with a compound annual growth rate (CAGR) of 6.2%. The growth during this forecasted period is believed to be driven by the increased use of biologics, the broadening scope of precision medicine, more streamlined drug approvals, wider reimbursements, and the proliferation of clinical trials. Key trends during this forecast period include the creation of combination therapies, progress in personalized medicine, the evolution of precision medicine, the incorporation of electronic health records, and strides made in biomarkers.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22103

How Are Emerging Segments Shaping the Polymyalgia Rheumatica Market Landscape?
The polymyalgia rheumatica market covered in this report is segmented -

1) By Treatment: Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs, Disease-Modifying Antirheumatic Drugs, Biologics
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Type: Adult, Geriatric, Periatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Corticosteroids: Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone
2) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Aspirin, Celecoxib
3) By Disease-Modifying Antirheumatic Drugs (DMARDs): Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine
4) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin-6 (IL-6) Inhibitors, B-Cell Inhibitors, Janus Kinase (JAK) Inhibitors

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22103&type=smp

Which Growth Factors Are Influencing Polymyalgia Rheumatica Market Expansion?
The progression of the polymyalgia rheumatica market is anticipated to be bolstered by the escalating demand for personalized medicine. This type of medical treatment is specifically designed to match an individual's genetic makeup, lifestyle, and particular health issues, offering more successful results. A variety of elements contribute to the increased demand for personalized medicine, such as advancements in genetic studies, rising patient hopes for custom therapies, and enhancements in diagnostic technology. Genetic studies allow for a more comprehensive exploration of individual genetic differences, enabling the development of treatments tailored to specific genetic indicators. By using the patient's unique features, personalized medicine can help choose the most suitable drugs, ensuring a safer and more effective treatment program. For example, as reported by the Personalised Medicine Coalition, a U.S.-based hospital and healthcare organization, in 2024, the Food and Drug Administration greenlit 16 new personalized treatments for patients with rare diseases in 2023, compared to just six in 2022. Hence, personalized medicine's surge is fuelling the growth of polymyalgia rheumatica market. The polymyalgia rheumatica market's growth is also predicted to be accelerated by the surge in telemedicine services. These services harness digital communication tools, like video and phone calls and online messaging, to offer patients remote medical consulting, diagnosis, treatment, and follow-up care without requiring face-to-face visits. The popularity of telemedicine services is due to the rising desire for convenient, cost-effective healthcare solutions. Telemedicine's ability to get rid of the need for physical visits is particularly attractive to patients seeking non-emergency consultations. Furthermore, telemedicine's expansion assists polymyalgia rheumatica (PMR) by allowing remote symptom monitoring, medication management, and regular check-ins, all crucial to handling chronic aches and swelling. For example, the Australian Bureau of Statistics, a governmental organization in Australia, reported in November 2024 that from 2022 to 2023, 87.7% of people used telehealth consultation, and this figure rose to 89.2% in 2023-24. Therefore, the surge in telemedicine services is fuelling the progression of the polymyalgia rheumatica market.

Who Are the Dominant Players Across Different Polymyalgia Rheumatica Market Segments?
Major companies operating in the polymyalgia rheumatica market are AbbVie Inc., Sanofi S.A., Eli Lilly and Co., Regeneron Pharmaceuticals Inc., Mount Sinai, NYU Langone Health, Mayo Foundation for Medical Education and Research, Hartford HealthCare, Horizon Therapeutics plc, Massachusetts General Hospital, Brigham and Women's Hospital, Stanford Health Care, University Hospitals Bristol NHS Foundation Trust, Circle Health Group Ltd., Siloam Hospital, UC San Diego Health, Vejthani Hospital, Sparrow Pharmaceuticals Inc., Johns Hopkins Arthritis Center, Upstate University Hospital

What Are the Latest Developing Trends in the Polymyalgia Rheumatica Market?
Key entities in the polymyalgia rheumatica industry are actively exploring the creation of innovative drugs such as interleukin-6 (IL-6) receptor blockers. Such biological medications aim to inhibit IL-6, a significant pro-inflammatory cytokine in autoimmune diseases and provide targeted treatment solutions. By preventing IL-6, the associated inflammation and symptoms are reduced, thereby improving the life quality of PMR patients. In February 2023, for example, US biotech firm Regeneron Pharmaceuticals, Inc., and French healthcare provider Sanofi, obtained FDA approval for Kevzara (sarilumab) for adult PMR patients who have either shown poor response to corticosteroids or who can't tolerate weaning off them. Kevzara, the first biologic of its kind approved for this purpose, operates by blocking IL-6-mediated signaling. The green light was given following a study in which 28.3% of subjects on sarilumab experienced sustained remission at 52 weeks, as opposed to 10.3% on a placebo2. The drug, which is also approved for treating moderately to severely active rheumatoid arthritis, is administered through a subcutaneous injection once every two weeks. Sanofi's stock (SNY) is presently trading at $54.13 on the NASDAQ.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/polymyalgia-rheumatica-global-market-report

Which Geographic Regions Are Expected to Dominate the Polymyalgia Rheumatica Market in the Coming Years?
Asia-Pacific was the largest region in the polymyalgia rheumatica market in 2024. The regions covered in the polymyalgia rheumatica market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Polymyalgia Rheumatica Market?
2. What is the CAGR expected in the Polymyalgia Rheumatica Market?
3. What Are the Key Innovations Transforming the Polymyalgia Rheumatica Industry?
4. Which Region Is Leading the Polymyalgia Rheumatica Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.